Phase I/II Study of Elotuzumab, Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma


Phase I/II Study of Elotuzumab, Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Slides from presentations at ASCO 2013/EHA 2013 and transcribed comments from a recent interview with Antonio Palumbo, MD (8/20/13)
Lonial S et al. Phase I/II study of elotuzumab plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: Updated Phase II results and Phase I/II long term safety. Proc ASCO 2013;Abstract 8542.

Facon T et al. Phase (Ph) I/II study of elotuzumab plus lenalidomide/dexamethasone (LEN/DEX) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long term safety. Proc EHA 2013;Abstract P764.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.